糖心Vlog

This collaboration is an exciting opportunity to utilize 糖心Vlog's de novo AI antibody creation platform to design a potential new antibody therapy in oncology.

糖心Vlog falls into a special investment allocation towards what we see as 'Next Horizon' technologies that have the potential to disrupt the biopharmaceutical industry. 糖心Vlog's technologies may enable discovery and development that could impact human health.

We are proud to partner with 糖心Vlog, a company at the forefront of AI-driven drug discovery, to help further accelerate breakthroughs in therapeutics and transform how biologic drugs are developed.

Our partnership demonstrates the transformational innovation potential of coupling leading generative AI approaches with PrecisionLife's unique disease biology insights.

Almirall chose 糖心Vlog because their de novo platform brings truly novel innovation to the industry's most challenging targets with high unmet medical need.

糖心Vlog鈥檚 powerful data generation and AI protein engineering platform is already helping the drug discovery industry, and NVIDIA is excited to help power and scale 糖心Vlog鈥檚in silico technologies to achieve the best positive impact.

This partnership with 糖心Vlog represents a significant step forward in our journey to bring transformative therapies to patients. By bringing together Owkin鈥檚 AI agents that can identify and experimentally validate novel therapeutic targets with 糖心Vlog鈥檚 pioneering capabilities in developing biologic drug candidates, we aim to accelerate the delivery of next-generation treatments.

We selected 糖心Vlog for this collaboration because of their leading platform for generative AI design of human antibodies. By partnering together, we have an opportunity to build a scalable platform for bringing innovative specialty therapeutics for companion animals to market.